Compare Box Inc (BOX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Box Inc trades at $32.86 (market cap $4.65B), while Ginkgo Bioworks Holdings Inc trades at $7.4 (market cap $515.15M). The key difference: Box Inc is far larger — about 9× Ginkgo Bioworks Holdings Inc's market cap, and Box Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BOX | DNA | |
|---|---|---|
Market Cap | $4.65B | $515.15M |
Sector | Technology | Health |
52-Week High | $33.60 | $16.14 |
52-Week Low | $21.37 | $5.48 |
Enterprise Value | $5.21B | $617.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX Inc. (NYSE: BOX) trades at $33.24, up 4.36% today, showing strong momentum near resistance levels. The company delivered solid Q1 2026 earnings beat with EPS of $0.37 versus $0.36 expected, continuing positive earnings surprises. Revenue growth accelerated to $1.09 billion in 2025 with net income margin expanding to 22.43%. Technical indicators show bullish momentum with the stock trading above key support levels and moving averages signaling strength.
BOX presents growth potential with strong revenue expansion and improving profitability, supported by recent enterprise contract wins like Quintas Energy's AI platform selection. However, elevated P/E ratio of 51.94 suggests premium valuation, while negative equity and high debt levels warrant monitoring. Analyst consensus remains bullish with $37 price target, representing 11% upside from current levels.
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
